Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Biochemical Engineering >  Inhibitors >  DNA damage >  DNA / RNA Synthesis inhibitors >  Nedaplatin

Nedaplatin

Basic information Safety Supplier Related

Nedaplatin Basic information

Product Name:
Nedaplatin
Synonyms:
  • (glycolato-o,o')diammineplatinum(ii)
  • cis-diammine(glycolato)platinum(ii)
  • NEDAPLATIN
  • 254-s
  • Aqupla
  • cis-diamine-glycolate-O,O'-platinum(II)
  • o(sup2))-diammine(hydroxyacetato(2-)-o(sup1(sp-4-3)-platinu
  • Nedaplait
CAS:
95734-82-0
MF:
C2H6N2O3Pt
MW:
301.17
Product Categories:
  • Inhibitors
  • Anticancer
  • Anticancer Platinum Agent
Mol File:
95734-82-0.mol
More
Less

Nedaplatin Chemical Properties

storage temp. 
Inert atmosphere,Store in freezer, under -20°C
More
Less

Nedaplatin Usage And Synthesis

Description

Nedaplatin, a novel second generation platinum complex, was marketed in Japan for the treatment of a variety of cancers including: head and neck, small-cell and non-small cell lung, oesophageal, prostatic, testicular, ovarian, cervical, bladder, and uterine cancers. Platinum anticancer agents, prototyped by cisplatin, have been reported to be hydrolyzed to the mono- or diaquated species of diamine platinum which react with nucleophilic sites on DNA to cause intrastrand and interstrand crosslinks and DNA-protein crosslinks, which result in cytotoxicity. Nedaplatin was reportedly more active than cisplatin against several solid tumors while sharing less nephro- and gastrointestinal toxicity to cisplatin in viva The minimal renal toxicity displayed by nedaplatin allows its use in patients with deteriorated renal function.

Originator

Shionogi (Japan)

Uses

anticancer

Uses

Nedaplatin is a platinum complex that has potent antineoplatic activity.

brand name

Aqupla

Pharmaceutical Applications

Nedaplatin, cis-diammineglycolatoplatinum(II), is structurally similar to carboplatin. The chemical structure consists of a central platinum(II) atom with two cis-ammonia groups as nonleaving groups and – in contrast to carboplatin – the dianionic form of glycolic acid as the leaving group. Nedaplatin has been approved for the clinical use in the Japanese market for the treatment of head and neck, testicular, ovarian, lung and cervical cancer. It is typically administered by IV injection and its dose-limiting side effect is myelosuppression.

NedaplatinSupplier

Hubei Zhongshan Medical Technology Co., Ltd Gold
Tel
027-61907345 13397111514
Email
w13397111514@163.com
J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Email
jkinfo@jkchemical.com
3B Pharmachem (Wuhan) International Co.,Ltd.
Tel
821-50328103-801 18930552037
Email
3bsc@sina.com
Chembest Research Laboratories Limited
Tel
021-20908456
Email
sales@BioChemBest.com
Wuhan Chemwish Technology Co., Ltd
Tel
86-027-67849912
Email
sales@chemwish.com